Paul Germonpre
Overview
Explore the profile of Paul Germonpre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
762
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berneman Z, De Laere M, Germonpre P, Huizing M, Willemen Y, Lion E, et al.
J Hematol Oncol
. 2025 Jan;
18(1):9.
PMID: 39849594
Cell therapies, including tumor antigen-loaded dendritic cells used as therapeutic cancer vaccines, offer treatment options for patients with malignancies. We evaluated the feasibility, safety, immunogenicity, and clinical activity of adjuvant...
2.
Van den Bossche J, De Laere M, Deschepper K, Germonpre P, Valcke Y, Lamont J, et al.
PLoS One
. 2024 Jul;
19(7):e0307204.
PMID: 39008481
Malignant pleural mesothelioma (MPM) is an aggressive cancer with a very poor prognosis. Recently, immune checkpoint inhibition (ICI) has taken center stage in the currently ongoing revolution that is changing...
3.
Van Der Steen N, Zwaenepoel K, Mazzaschi G, Luirink R, Geerke D, Op de Beeck K, et al.
Molecules
. 2019 Dec;
24(24).
PMID: 31817278
The c-Met receptor is a therapeutically actionable target in non-small-cell lung cancer (NSCLC), with one approved drug and several agents in development. Most suitable biomarkers for patient selection include c-Met...
4.
Germonpre P, Van den Wyngaert T
PLoS One
. 2019 Apr;
14(4):e0215135.
PMID: 30973926
Introduction: Little data is available on patients with advanced non-squamous NSCLC treated with erlotinib specifically after failure of first-line pemetrexed-containing chemotherapy. We assessed the effectiveness, safety and tolerability of erlotinib...
5.
Sorber L, Zwaenepoel K, De Winne K, van Casteren K, Augustus E, Jacobs J, et al.
Cancers (Basel)
. 2018 Aug;
10(9).
PMID: 30150518
A multicenter study was performed to determine an optimal workflow for liquid biopsy in a clinical setting. In total, 549 plasma samples from 234 non-small cell lung cancer (NSCLC) patients...
6.
Tournoy K, Thomeer M, Germonpre P, Derijcke S, De Pauw R, Galdermans D, et al.
Lung Cancer
. 2018 Jan;
115:49-55.
PMID: 29290261
Objectives: In patients with refractory or recurrent non-small-cell lung cancer (NSCLC) after first line chemotherapy, phase III trials showed superiority of nivolumab, an IgG4 programmed death-1 immune-checkpoint-inhibitor antibody, over docetaxel....
7.
Van Der Steen N, Mentens Y, Ramael M, Leon L, Germonpre P, Ferri J, et al.
Clin Lung Cancer
. 2017 Aug;
19(1):35-41.
PMID: 28757336
Several oncogenic drivers have been identified in non-small cell lung cancer. Targeted therapies for these aberrations have already been successfully developed and implemented in clinical practice. Owing to improved sensitivity...
8.
Ninane V, Corhay J, Germonpre P, Janssens W, Joos G, Liistro G, et al.
Int J Chron Obstruct Pulmon Dis
. 2017 Mar;
12:793-801.
PMID: 28293106
Background: Global Initiative for Chronic Obstructive Lung Disease (GOLD) global strategy (2015) provides guidance for the treatment of chronic obstructive pulmonary disease (COPD) with different first-choice options per GOLD category...
9.
Van Der Steen N, Deben C, Deschoolmeester V, Wouters A, Lardon F, Rolfo C, et al.
World J Clin Oncol
. 2016 Dec;
7(6):425-432.
PMID: 28008383
Aim: To investigate the potential benefit of combining the cMET inhibitor crizotinib and cisplatin we performed combination studies. Methods: We tested three different treatment schemes in four non-small cell lung...
10.
Rolfo C, Passiglia F, Castiglia M, Raez L, Germonpre P, Gil-Bazo I, et al.
Transl Lung Cancer Res
. 2015 Mar;
3(4):250-61.
PMID: 25806308
The last few decades have witnessed a silent revolution in the war against NSCLC, thanks to the discovery of "oncogenic drivers" and the subsequent development of targeted therapies. The discovery...